WASHINGTON, DC / ACCESS Newswire / March 24, 2026 / A new federal initiative allowing up to $500 annually in hemp-derived cannabinoid products for Medicare beneficiaries is raising urgent questions ...
The Centers for Medicare & Medicaid Services (CMS) issued a ground-breaking draft national coverage decision (NCD) on January 11, 2022, for Food & Drug Administration (FDA) approved monoclonal ...
In the wake of the Food and Drug Administration’s (FDA’s) controversial decision to approve aducanumab for Alzheimer’s disease, how will, and how should, Medicare respond? We propose a coverage with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results